« Back to Medicines list

Efexor XL 150 mg hard prolonged release capsules

  • Name:

    Efexor XL 150 mg hard prolonged release capsules

  • Company:
    info
  • Active Ingredients:

    venlafaxine hydrochloride

  • Legal Category:

    Product subject to medical prescription which may not be renewed (A)

Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 06/10/20

files-icon(Click to Download)
Summary of Product Characteristics last updated on medicines.ie: 6/10/2020

Click on this link to Download PDF directly

Pfizer Healthcare Ireland

Pfizer Healthcare Ireland

Company Products

Medicine NameActive Ingredients
Medicine Name Accupro 10 mg Film - Coated tablets Active Ingredients Quinapril hydrochloride
Medicine Name Accupro 20 mg Film - Coated tablets Active Ingredients Quinapril hydrochloride
Medicine Name Accupro 40 mg Film - Coated tablets Active Ingredients Quinapril hydrochloride
Medicine Name Accupro 5 mg Film - Coated tablets Active Ingredients Quinapril hydrochloride
Medicine Name Accuretic 20 mg/12.5 mg Tablets Active Ingredients Hydrochlorothiazide, Quinapril hydrochloride
Medicine Name Aciclovir 25 mg/ml Concentrate for Solution for Infusion. Active Ingredients Aciclovir sodium
Medicine Name Aldactone 100mg film coated tablets Active Ingredients Spironolactone
Medicine Name Aldactone 25mg film-coated tablets Active Ingredients Spironolactone
Medicine Name Aldactone 50 mg Film-coated tablets. Active Ingredients Spironolactone
Medicine Name Amlodipine Pfizer 10 mg Tablets Active Ingredients Amlodipine besilate
Medicine Name Amlodipine Pfizer 5 mg Tablets Active Ingredients Amlodipine besilate
Medicine Name Anugesic HC Cream Active Ingredients Balsam Peru, Benzyl Benzoate, Bismuth Oxide, Hydrocortisone Acetate, Pramocaine Hydrochloride, Zinc Oxide
Medicine Name ARICEPT 10 mg film coated tablets Active Ingredients Donepezil Hydrochloride
Medicine Name ARICEPT 5 mg film coated tablets Active Ingredients Donepezil Hydrochloride
Medicine Name Aromasin 25 mg coated tablets Active Ingredients Exemestane
Medicine Name Arthrotec 50 Active Ingredients Diclofenac Sodium, Misoprostol
Medicine Name Arthrotec 75 modified-release tablets Active Ingredients Diclofenac Sodium, Misoprostol
Medicine Name Ativan 1mg Tablets Active Ingredients Lorazepam
Medicine Name ATIVAN INJECTION Active Ingredients Lorazepam
Medicine Name BeneFIX Active Ingredients nonacog alfa
Medicine Name BESPONSA 1 mg powder for concentrate for solution for infusion Active Ingredients Inotuzumab ozogamicin
Medicine Name Bosulif 100 mg, 400 mg & 500 mg film-coated tablets Active Ingredients Bosutinib monohydrate
Medicine Name Cabaser 1mg Tablet Active Ingredients Cabergoline
Medicine Name Cabaser 2mg Tablet Active Ingredients Cabergoline
Medicine Name CAMPTO 20 mg/ml, concentrate for solution for infusion Active Ingredients Irinotecan hydrochloride trihydrate
1 - 0 of 231 items.Total: Infinity pages

When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 6 October 2020

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.8 - Undesirable effects
  • Change to section 5.1 - Pharmacodynamic properties

Free text change information supplied by the pharmaceutical company

SPC has been updated as follows:  

 Information regarding discontinuation of treatment with Venlafaxine has been updated in following sections.

Section 4.2 Posology and method of administration.

Section 4.4 Special warnings and precautions for use.

Section 4.8 Undesirable effects

Section 5.1 Pharmacodynamic properties

Updated on 6 October 2020 PIL

Reasons for updating

  • Change to section 1 - what the product is used for
  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 3 - overdose, missed or forgotten doses
  • Change to section 4 - how to report a side effect
  • Change to section 6 - date of revision

Updated on 8 July 2020 PIL

Reasons for updating

  • Change to section 6 - marketing authorisation holder

Updated on 21 February 2020

Reasons for updating

  • Change to section 4.8 - Undesirable effects

Free text change information supplied by the pharmaceutical company

The SPC: Updated as follows,

Section 4.8 has been updated with the addition of adverse drug reaction (ADR) ‘takotsubo cardiomyopathy’ to Section 4.8 “Undesirable effects” of the venlafaxine hydrochloride Summary of Product Characteristics (SmPC) in line with the company Core Data Sheet (CDS) for the above products. PIL has been updated accrodingly.

Updated on 21 February 2020 PIL

Reasons for updating

  • Change to section 4 - possible side effects
  • Change to section 6 - date of revision

Updated on 13 August 2019 PIL

Reasons for updating

  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 6 - date of revision

Updated on 13 August 2019

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use

Updated on 27 November 2018

Reasons for updating

  • Improved presentation of SmPC

Free text change information supplied by the pharmaceutical company

Improved presentation of SPC uploaded

Updated on 27 November 2018

Reasons for updating

  • Improved presentation of SmPC

Free text change information supplied by the pharmaceutical company

Improved presentation of SPC uploaded

Updated on 28 August 2018

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 10 - Date of revision of the text

Free text change information supplied by the pharmaceutical company

The SPC has been updated as follows:
Section 4.4 – update to include reference to amphetamines

Section 4.5 – update to include reference to amphetamines

Section 10 – update Date of Revision of text 10 07/2018

Updated on 16 July 2018

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

The SPC has been updated as follows:
Section 4.4 – update to include reference to amphetamines

Section 4.5 – update to include reference to amphetamines

Section 10 – update Date of Revision of text 10 07/2018

Updated on 16 July 2018 PIL

Reasons for updating

  • Change to section 2 - interactions with other medicines, food or drink
  • Change to section 6 - date of revision

Updated on 30 May 2018

Reasons for updating

  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

The SPC has been updated as follows:
Section 4.5 updated to included details of interaction with cytochrome P450 and oral contraceptives.

Updated on 9 March 2018

Reasons for updating

  • New SmPC for new product

Legal category: Product subject to medical prescription which may not be renewed (A)

Updated on 9 March 2018 SPC

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.9 - Overdose
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

The SPC has been updated as follows:

Section 5.1 updated with a new section ‘Cardiac electrophysiology’ to include detail of  QT interval prolongation.

Section 4.4 updated to cross reference Section 5.1.

Section 4.9 updated to cross reference Section 5.1.

Section 5.1 – b.i.d. updated to ‘twice daily’.

Section 10 – Date of Revision of text updated to reflect approval date (03/2018). Ref number also updated.

Updated on 8 July 2016 PIL

Reasons for updating

  • New PIL for new product

Updated on 8 July 2016 PIL

Reasons for updating

  • Correction of spelling/typing errors

Updated on 24 June 2016 SPC

Reasons for updating

  • Change to section 4.8 - Undesirable effects

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Re-assignment of frequency categories for the adverse drug reactions (ADRs) in Section 4.8

Updated on 23 June 2016 PIL

Reasons for updating

  • Change to side-effects
  • Change to date of revision

Updated on 9 February 2016 SPC

Reasons for updating

  • Change to section 9 - Date of renewal of authorisation

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

lease find attached an updated SPC for Efexor XL 37.5mg, 75mg and 150mg Capsules , the update is to add the ‘Date of last renewal’ to section 9 of the SPC and a change to the regulatory ref number from 12_0 to 12_1.

Updated on 1 February 2016 SPC

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.6 - Pregnancy and lactation

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

QRD updates to most sections of the SPC

Section 4.6 - Addition of text on Fertility

Section 4.8 – Addition of reporting of side effects

Updated on 29 January 2016 PIL

Reasons for updating

  • Change to warnings or special precautions for use
  • Change to instructions about missed dose
  • Change to storage instructions
  • Change to side-effects
  • Change to drug interactions
  • Change to information about pregnancy or lactation
  • Change to date of revision
  • Change to improve clarity and readability

Updated on 26 January 2015 SPC

Reasons for updating

  • Change to section 6.5 - Nature and contents of container
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Update to section 6.5 – Nature and contents of Container.

-       Removal of PVC/Aclar/Aluminium foil from this section.

Update section 10 - Date of revision of text to January 2015.

Updated on 21 January 2015 PIL

Reasons for updating

  • Change to date of revision
  • Addition of manufacturer

Updated on 11 August 2014 SPC

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Updates to sections 4.4 & 4.5

Updated on 6 August 2014 PIL

Reasons for updating

  • Change to warnings or special precautions for use
  • Change to drug interactions
  • Change to date of revision

Updated on 2 October 2013 SPC

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Section 4.4 – Update to wording on Serotonin syndrome and abnormal bleeding

Section 4.5 - Update to wording on Serotonin syndrome

Updated on 27 September 2013 PIL

Reasons for updating

  • Change to drug interactions
  • Change to date of revision

Updated on 7 February 2013 SPC

Reasons for updating

  • New individual SPC (was previously included in combined SPC)

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

None provided

Updated on 4 February 2013 PIL

Reasons for updating

  • Change to side-effects
  • Change to date of revision

Updated on 4 July 2012 PIL

Reasons for updating

  • Change to drug interactions
  • Change to date of revision

Updated on 9 March 2012 PIL

Reasons for updating

  • Correction of spelling/typing errors

Updated on 8 February 2012 PIL

Reasons for updating

  • Change to side-effects
  • Change to date of revision

Updated on 26 August 2011 PIL

Reasons for updating

  • Change to storage instructions
  • Change to date of revision
  • Change due to harmonisation of PIL
  • Introduction of new pack/pack size

Updated on 16 August 2011 PIL

Reasons for updating

  • Change of manufacturer
  • Change to warnings or special precautions for use
  • Change to date of revision

Updated on 13 January 2011 PIL

Reasons for updating

  • Change to warnings or special precautions for use
  • Change to side-effects
  • Change to drug interactions
  • Change to information about pregnancy or lactation

Updated on 25 February 2009 PIL

Reasons for updating

  • Change due to harmonisation of patient information leaflet

Updated on 3 June 2008 PIL

Reasons for updating

  • Change to warnings or special precautions for use

Updated on 8 January 2008 PIL

Reasons for updating

  • Change to, or new use for medicine
  • Change to warnings or special precautions for use
  • Addition of joint PIL covering all presentations
  • Change to dosage and administration

Updated on 25 October 2007 PIL

Reasons for updating

  • Change to warnings or special precautions for use
  • Change to storage instructions

Updated on 20 February 2007 PIL

Reasons for updating

  • Correction of spelling/typing errors

Updated on 11 September 2006 PIL

Reasons for updating

  • Improved electronic presentation
  • Change to warnings or special precautions for use
  • Change of contraindications
  • Change to drug interactions
  • Change to information about pregnancy or lactation
  • Correction of spelling/typing errors
  • Change to date of revision
  • Change to instructions about overdose
  • Change to storage instructions

Updated on 29 June 2006 PIL

Reasons for updating

  • Change to warnings or special precautions for use
  • Change of contraindications
  • Change to side-effects
  • Change to date of revision

Updated on 27 June 2005 PIL

Reasons for updating

  • New PIL for medicines.ie